Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04811027 · ClinicalTrials.gov registry record · Phase 2
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
A Phase 2 study, sponsored by Immutep S.A.S..
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT04811027 is a Phase 2 study that has completed, run by Immutep S.A.S.. The registered enrollment target is 171 participants.
The verdict
NCT04811027, a Phase 2 study, has completed, sponsored by Immutep S.A.S..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with programmed death-ligand 1 (PD-L1) positive (combined positive score \[CPS\] ≥1) tumors, and determine the efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors.
Interventions
- DRUG pembrolizumab (KEYTRUDA®)
- DRUG eftilagimod alpha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2025-11-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04811027
The ClinicalTrials.gov registry entry for NCT04811027 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immutep S.A.S., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab (KEYTRUDA®) is the first listed.
NCT04811027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04811027 about?
NCT04811027 is a clinical study titled "Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC". Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with programmed death-ligand 1 (PD-L1) positive (combined positive score \[CPS\] ≥1) tumors, and determine the efficacy and safety of efti plu...
What is the current status of trial NCT04811027?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2021-08-27. Estimated completion is 2025-11-05.
What interventions are being tested in trial NCT04811027?
The interventions under investigation include: pembrolizumab (KEYTRUDA®) (DRUG), eftilagimod alpha (DRUG).
Who is sponsoring clinical trial NCT04811027?
This trial is sponsored by Immutep S.A.S., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.